Seroquel vs. Vraylar

See how Seroquel and Vraylar compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Seroquel and Vraylar are both atypical antipsychotics approved for schizophrenia and bipolar disorder, but they differ in dosing schedule, side effects, and price.

  • Seroquel is taken two to three times a day and tends to cause sedation and weight gain, while once-daily Vraylar is more likely to cause restlessness and movement-related side effects.

  • Seroquel is available as a low-cost generic, while Vraylar is brand-only and can cost roughly $1,500 to $2,100 a month without insurance.

Seroquel vs. Vraylar Drug Summary

Seroquel

Seroquel (quetiapine) is an atypical antipsychotic approved for schizophrenia, manic or mixed episodes of bipolar I disorder, and bipolar depression. It's taken by mouth, usually two to three times a day, with the dose increased gradually over the first several days of treatment.

Vraylar

Vraylar (cariprazine) is an atypical antipsychotic approved for schizophrenia, manic or mixed episodes of bipolar I disorder, bipolar depression, and as an add-on for major depressive disorder. It's taken by mouth once a day, with the dose increased after the first day based on response.

Seroquel vs. Vraylar Side Effects

Seroquel

Most common
Somnolence (up to 18%)
Dizziness (up to 11%)
Dry mouth (up to 9%)
Constipation (up to 8%)

Vraylar

Most common
Akathisia (up to 11%)
Somnolence (up to 7%)
Dyspepsia (up to 7%)
Restlessness (up to 7%)

Seroquel vs. Vraylar Dosage

Seroquel

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 50 mg/day Day 1
Maximum dose 150-750 mg/day Day 5 onward
Dose changes 4 increases Every day

Vraylar

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1.5 mg once daily Day 1
Maximum dose 6 mg once daily If needed
Dose changes 3 increases Every day

Seroquel vs. Vraylar Indications

Seroquel

Seroquel is FDA-approved for schizophrenia in adults and adolescents, for manic or mixed episodes of bipolar I disorder, for depressive episodes of bipolar disorder, and as long-term add-on therapy for bipolar I maintenance. It is not approved on its own for major depressive disorder outside of bipolar illness.

  • Schizophrenia (adults and adolescents 13-17)

  • Acute manic or mixed episodes of bipolar I disorder

  • Depressive episodes of bipolar disorder

  • Maintenance treatment of bipolar I, as an add-on

Vraylar

Vraylar is FDA-approved for schizophrenia in adults and adolescents, for manic or mixed episodes of bipolar I disorder, for depressive episodes of bipolar I disorder, and as an add-on treatment for major depressive disorder in adults already taking an antidepressant.

  • Schizophrenia (adults and adolescents 13+)

  • Acute manic or mixed episodes of bipolar I disorder

  • Depressive episodes of bipolar I disorder

  • Add-on treatment for major depressive disorder

Seroquel vs. Vraylar Pros and Cons

Seroquel

Seroquel has decades of real-world use and is available as an inexpensive generic in many tablet strengths, which makes long-term treatment more affordable. Its main tradeoffs are sedation and weight gain, which can affect daily functioning and metabolic health.

Pros

  • Available as a low-cost generic (quetiapine)

  • Long track record of use, approved since 1997

  • Sedating effect can help with sleep and agitation

  • Wide range of tablet strengths for flexible dosing

Cons

  • Requires multiple daily doses for most indications

  • Higher risk of sedation and weight gain than some options

  • Needs a slower titration over several days at start

  • Not approved as a standalone MDD treatment

Vraylar

Vraylar's once-daily dosing and long half-life make it more forgiving of an occasional missed dose, and it carries a lower burden of sedation and weight gain in trials than many older antipsychotics. Its main tradeoffs are a higher rate of movement-related side effects and a brand-only price that can run roughly $1,500 to $2,100 a month without insurance.

Pros

  • Once-daily dosing simplifies the regimen

  • Lower rates of sedation and weight gain in trials

  • Long half-life buffers the effect of a missed dose

  • Approved as an add-on specifically for MDD

Cons

  • Higher rates of akathisia and movement-related effects

  • No generic yet; brand-only, roughly $1,500 to $2,100 per month without insurance

  • Full effect of a dose change can take weeks to show up

  • Newer drug with a shorter real-world track record

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.